In the GEO database, the expression levels of MET, ETS-1, and USP9X in osimertinib-resistant lung cancer cells, as observed in the datasets GSE202859 and GSE236654, were significantly higher than those found in osimertinib-sensitive lung cancer cells (Supplementary Fig. 4A, B). This evidence concerns the gene MET and lung carcinoma.